Septerna, Inc.
SEPN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SEPN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SEPN
Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small-molecule drugs targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex™ platform, with its lead candidate SEP-631 entering Phase 1 trials.
Key risk: Clinical development risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Septerna, Inc..
Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small-molecule drugs targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex™ platform, with its lead candidate SEP-631 entering Phase 1 trials.
- Septerna's lead product candidate, SEP-631, is a novel oral small-molecule PTH1R agonist for hypoparathyroidism, with Phase 1 clinical trial initiation expected in late 2026 or early 2027 [sec_mda · as of 2026-05-11].
- As of June 30, 2026, Septerna reported cash and equivalents of $84.7M, total revenue of $26.7M, and a net loss of $13.0M [sec].
- The company has incurred significant operating losses since inception, except for the year ended December 31, 2023, and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-08-10].
- Septerna's revenue to date has been generated solely from research services, and it has not yet generated any product revenue [sec_mda · as of 2026-05-11].
What works
- Septerna's Native Complex™ platform is a structure-based drug discovery approach targeting GPCRs, a validated class of drug targets, potentially enabling the development of oral small-molecule therapies [sec_mda · as of 2026-03-09].
- The company has secured significant non-dilutive funding, including a $195.0M upfront payment from a collaboration with Novo Nordisk in July 2025 and a $12.5M milestone from Vertex in August 2025, bolstering its financial runway [sec_mda · as of 2026-03-09].
- As of December 31, 2025, Septerna had cash, cash equivalents, and marketable securities of $548.7M, which management believes will fund operations at least into 2029 [sec_mda · as of 2026-03-09].
What to weigh
- Septerna has a history of significant operating losses, except for 2023, and expects to continue incurring net losses for the foreseeable future as it advances its pipeline [sec_mda · as of 2026-08-10].
- The company has not yet generated any product revenue and its ability to do so depends on the successful development, regulatory approval, and commercialization of its product candidates, which is uncertain [sec_mda · as of 2025-11-10].
- Septerna's future funding requirements are subject to numerous risks and uncertainties, including the scope, timing, and results of preclinical and clinical trials, and the company may need additional capital to complete development [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Septerna expects to initiate a Phase 1 trial for SEP-631 in late 2026 or early 2027.
“trial in late 2026 or early 2027.”
SEC MD&A · May 11, 2026
Septerna has incurred significant operating losses since inception, except for 2023.
“We have incurred significant operating losses since our inception, except for the year ended December 31, 2023.”
SEC MD&A · May 11, 2026
Septerna's revenue to date has been generated solely from research services.
“Our revenue to date has been generated solely from research services.”
SEC MD&A · May 11, 2026
Risks & what to watch (4)›
Key risks
- Clinical development risk — SEP-631 and other candidates may fail in clinical trials, delaying or preventing regulatory approval [sec_mda · as of 2026-08-10].
- No product revenue history — Septerna has not generated any product revenue and depends on future commercialization success [sec_mda · as of 2025-11-10].
- Funding uncertainty — Future capital needs are uncertain; additional funding may be required to complete development [sec_mda · as of 2026-08-10].
- Reliance on collaborations — Revenue and milestones depend on partnerships (e.g., Novo, Vertex) which may not continue [sec_mda · as of 2026-03-09].
What to watch
- Initiation of Phase 1 clinical trial for SEP-631, expected in late 2026 or early 2027 [sec_mda · as of 2026-05-11].
- Progress of the Native Complex™ platform in advancing additional GPCR-targeted candidates into preclinical and clinical stages [sec_mda · as of 2026-03-09].
- Financial runway and cash burn rate, given the company's expectation of continued net losses [sec_mda · as of 2026-08-10].
- Potential new collaboration or milestone payments from existing partners (Novo Nordisk, Vertex) [sec_mda · as of 2026-03-09].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Septerna, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Septerna, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
49.4 months
D/E 0.47 · 0% dilution
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
0 buys · 21 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
123
Total value held
$1.07B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 6,995,858 | $168.1M |
| trv gp v, llc | 6,215,591 | $149.4M |
| driehaus capital management llc | 4,395,572 | $105.6M |
| trv gp vi, llc | 4,211,659 | $101.2M |
| samsara biocapital, llc | 3,149,128 | $75.7M |
| goldman sachs group inc | 2,906,427 | $69.8M |
| vanguard capital management llc | 2,393,924 | $57.5M |
| blackrock, inc. | 1,822,174 | $43.8M |
| janus henderson group plc | 1,781,508 | $42.7M |
| bvf inc/il | 1,353,249 | $32.5M |
Showing top 10 of 123 institutional holders of Septerna, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 9.4%
- Days to cover
- 8.8
- Shares short
- 2,457,303
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SEPN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Septerna, Inc.?
Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small-molecule drugs targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex™ platform, with its lead candidate SEP-631 entering Phase 1 trials.
What is Septerna, Inc.'s lead drug candidate?
Septerna, Inc.'s most advanced tracked candidate is pth1r agonist (Preclinical) for hypoparathyroidism.
Who is the CEO of Septerna, Inc.?
Dr. Jeffrey T. Finer M.D., Ph.D. is the chief executive officer of Septerna, Inc. (SEPN).
Where is Septerna, Inc. headquartered?
Septerna, Inc. (SEPN) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Septerna, Inc. focus on?
Septerna, Inc. develops therapies across Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.